Q-omics provides the consensus-scored ZSCAN18 profile across patient tissues and cancer cell-line models. ZSCAN18 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZSCAN18 is differentially expressed in 17, with the highest sampling consensus in KICH. Additionally, ZSCAN18 protein abundance shows 19,982 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, KICH, and BRCA as cancer lineages where ZSCAN18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSCAN18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSCAN18 survival associations across molecular data types. ZSCAN18 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSCAN18 RNA expression–survival associations across cancer types. High ZSCAN18 expression shows unfavorable associations in LGG and LUSC, but favorable associations in UVM, LUAD, PAAD and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZSCAN18 RNA expression.
This table summarizes ZSCAN18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZSCAN18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSCAN18 shows lower tumor expression in KICH, HNSC, COAD, LUAD, BLCA and KIRC. The KICH box plot shows higher ZSCAN18 RNA expression in normal versus tumor tissue (log2 FC = −1.882, t-test p < 0.001).
This table shows molecular features associated with ZSCAN18 in patient tissues and cancer cell lines. In patient samples, ZSCAN18 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSCAN18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
